Yew Bio-Pharm Group, Inc.
YEWB · OTC
9/30/2021 | 6/30/2021 | 3/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.04 | -0.00 | 0.02 |
| FCF Yield | -69.31% | 18.41% | -40.94% | -20.04% |
| EV / EBITDA | -49.50 | 63.55 | 5.20 | 18.26 |
| Quality | ||||
| ROIC | -2.98% | -0.51% | 1.17% | -0.04% |
| Gross Margin | -762.96% | -1.54% | 10.95% | 5.11% |
| Cash Conversion Ratio | -3.78 | -3.31 | -0.27 | -12.21 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.56% | -3.57% | -9.62% | -10.11% |
| Free Cash Flow Growth | -386.91% | 172.72% | -118.26% | -832.68% |
| Safety | ||||
| Net Debt / EBITDA | -27.33 | 31.14 | 3.15 | 11.08 |
| Interest Coverage | -11.76 | -2.21 | 5.70 | -0.16 |
| Efficiency | ||||
| Inventory Turnover | 7.72 | 136.69 | 549.38 | 348.24 |
| Cash Conversion Cycle | 11,020.22 | 109.07 | -11.62 | -3.59 |